Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001
June 29 2020 - 9:30AM
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a
clinical-stage global developer of cell-based technologies and
therapeutics, announced today it has successfully completed Phase I
first-in-human clinical study of its leading Chimeric Antigen
Receptor (CAR) T-cell therapy candidate, AVA-001 (National
Institute of Health clinical trial registration number:
NCT03952923). Nine out of ten patients with
relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
have achieved complete remission (CR rate of 90%) within one month
after the initiation of AVA-001 CAR T-cell therapy treatment.
The treatment with AVA-001 was generally well tolerated with
minimal toxicities and adverse side effects. No neurotoxicity
or greater than Grade-1 cytokine release syndrome was observed in
this cohort of patients treated with AVA-001. All patients
who achieved CR successfully proceeded to allogeneic bone marrow
transplant with curative intent. AVA-001 is a third
generation CAR T-cell therapy which involves the 4-1BB (or CD28)
co-stimulation signaling pathway. Accessary laboratory
testing that accompanied this pilot clinical study has demonstrated
evidence of enhancement in CAR T cell persistence and protection
against CAR T cell exhaustion.
Avalon will present the results of this AVA-001 Phase 1 clinical
trial on July 11,2020 at The Eighth Annual Lu Daopei Hematology
Forum, the largest Hematology Conference in Asia (which will be
held online according to the organizer due to the COVID-19
pandemic).
“We are excited and pleased to achieve these successful outcomes
with our AVA-001 CAR T-cell therapy. This paradigm of
bridging CAR T-cell therapy to bone marrow transplant creates a new
therapeutic horizon with curative potential for patients with
relapsed/refractory B-ALL and other hematologic cancers,” stated
David Jin, M.D., Ph.D., President and Chief Executive Officer of
Avalon GloboCare. “We look forward to advancing our mission to
improve cancer patient care and save lives,” said Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage,
vertically-integrated, leading CellTech bio-developer dedicated to
advancing and empowering innovative, transformative immune effector
cell therapy, exosome technology, as well as COVID-19 related
diagnostics and therapeutics. Avalon also provides strategic
advisory and outsourcing services to facilitate and enhance its
clients' growth and development, as well as competitiveness in
healthcare and CellTech industry markets. Through its
subsidiary structure with unique integration of verticals from
innovative R&D to automated bioproduction and accelerated
clinical development, Avalon is establishing a leading role in the
fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEXTM), and regenerative therapeutics. For more
information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute "forward-looking statements." Forward-looking statements
provide current expectations of future events based on certain
assumptions and include any statement that does not directly relate
to any historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors as disclosed in our
filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information: Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024